Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia
Authors' conclusion
Administration of intranasal dexmedetomidine in the supine position during general anaesthesia is feasible with good bioavailability. This administration method has slower absorption when compared to awake patients in upright position, with consequent concentrations attained after TMAX for several hours.
Study context
- Population
- Adults 35–80 y, ASA 1–3, weight 50–100 kg, undergoing elective unilateral total hip or knee arthroplasty under GApooled with IV data (n = 202)
- Participants
- 28 adults
- Outcome
- Absorption pharmacokinetics (CMAX, TMAX, relative bioavailability, absorption half-time) and feasibility
Methodological detailssingle-group, population pharmacokinetic analysis (nonlinear mixed effects), simulation (n = 1000)
- Single-group
- Population pharmacokinetic analysis (nonlinear mixed effects)
- Simulation (n = 1000)
Main finding
As reported in the abstract
Absorption PK of intranasal dexmedetomidine
CMAX
0.273 μg L-1
TMAX
98 min
Relative bioavailability
80%
95% CI 75–91%
Absorption half-time (TABS), slower than in previous PK studies on adult patients
120 min
95% CI 90–147 min
Further findings
Weight-adjusted dose of dexmedetomidine
- Mean (SD) weight-adjusted dose
- 1.22 (0.15) μg kg-1
Safety
Perioperative haemodynamics
- Remained stable in all patients
Original publication
Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia. Acta Anaesthesiol Scand. Published 19 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →